Sunday, 4 October 2026European Markets

SOLUTIONS 30 SE Stock Over 14% Down So Far Today

Loading stream...

(vianews) - shares of solutions 30 se (cac 40: s30.pa) dropped by a staggering 14.47% to €1.90 at 11:05 est on friday, after three sequential sessions in a row of losses. cac 40 is dropping 0.03% to €7,536.63, following the last session's downward trend. this seems, up until now, a somewhat down trend trading session today.

solutions 30 se's last close was €2.29, 69.84% under its 52-week high of €7.60.

about solutions 30 se

solutions 30 se provides support solutions for new digital technologies in france, italy, germany, the netherlands, belgium, luxembourg, poland, and spain. the company offers telecom support services, including installation, assistance using communications equipment, deployment of telecommunication infrastructure, maintenance, and logistics. it also provides it solutions, such as installation and maintenance of it hardware, it infrastructure, and servers; implementation of automatized robotic processes; deployment and maintenance of internet of things; totem/kiosk design, manufacturing, installation, and maintenance; console creation for data analytics; and logistics of spare parts and systems. in addition, the company installs and maintains smart meters; charging stations for electric vehicles; photovoltaic power plants for professional and residential markets; smart appliances comprising thermostats, light bulbs, plugs, and sensors; and l/h gas converters, as well as point of sale equipment and digital signs. further, it deploys and maintains self-check-out technology and store digital infrastructure; installs wired and wireless connectivity, access control systems, and intrusion alarm systems; deploys fire alarm systems and video/cctv; and offers cabling and logistics services. the company was incorporated in 2003 and is based in luxembourg, luxembourg.

earnings per share

as for profitability, solutions 30 se has a trailing twelve months eps of €-0.04.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -1.85%.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, solutions 30 se's stock is considered to be overbought (>=80).

sales growth

solutions 30 se's sales growth for the current quarter is negative 3.7%.

yearly top and bottom value

solutions 30 se's stock is valued at €1.90 at 11:05 est, way below its 52-week high of €7.60 and way higher than its 52-week low of €1.58.

revenue growth

year-on-year quarterly revenue growth grew by 0.7%, now sitting on 879.25m for the twelve trailing months.

more news about solutions 30 se (s30.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com